Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
Top Cited Papers
- 31 December 2007
- journal article
- review article
- Published by Elsevier
- Vol. 11 (1-2) , 32-50
- https://doi.org/10.1016/j.drup.2007.11.003
Abstract
No abstract availableKeywords
This publication has 229 references indexed in Scilit:
- FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcomeBritish Journal of Cancer, 2007
- A transforming mutation in the pleckstrin homology domain of AKT1 in cancerNature, 2007
- Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignanciesPublished by Elsevier ,2007
- Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacyBritish Journal of Cancer, 2007
- A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomasBritish Journal of Cancer, 2006
- Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?British Journal of Cancer, 2006
- A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in gliomaCancer Cell, 2006
- Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancerNature Medicine, 2005
- Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol‐3 kinase pathways in non‐small cell lung cancer cellsInternational Journal of Cancer, 2005
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004